Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which specializes in the research and development of products for the aging population. The company markets NicAlertTM and TobacAlertTM, tests that use urine or saliva to detect use of tobacco products. It develops NX-1207, a novel treatment for benign prostatic hyperplasia, which is in Phase 3 clinical trials. It also has pipeline drug candidates aimed at the causes of Alzheimer's disease and new treatments of bacterial infections in humans. Nymox Pharmaceutical was founded by Paul Averback on May 30, 1995 and is headquartered in Saint-Laurent, Canada.